[{"bbox": [89, 97, 370, 133], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [91, 201, 588, 235], "category": "Section-header", "text": "## Market Landscape by End User Usability"}, {"bbox": [99, 275, 913, 312], "category": "Caption", "text": "Chart 18: India In-Vitro Diagnostics Landscape - By End User Usability"}, {"bbox": [101, 337, 1351, 1199], "category": "Picture"}, {"bbox": [101, 1199, 617, 1230], "category": "Text", "text": "Source – Imarc Research, CareEdge Research"}, {"bbox": [89, 1259, 1561, 1453], "category": "Text", "text": "The India In-Vitro Diagnostics (IVD) market, segmented by end-user usability, is significantly driven by hospital and clinical laboratories, which remain the primary diagnostic service providers. In CY24, hospital laboratories accounted for 583 Million USD, projected to grow to 1,109 Million USD by CY30, reflecting their critical role in comprehensive diagnostic testing. Similarly, clinical laboratories held a market share of 458 Million USD in CY24 and are expected to reach 908 Million USD by CY30, emphasizing their importance in routine and specialized testing. Other end-user segments, including point-of-care testing centres, patient self-testing, academic institutes, and others, continue to gain momentum."}, {"bbox": [99, 1489, 584, 1522], "category": "Caption", "text": "Chart 19: Market Share by End User Usability"}, {"bbox": [101, 1520, 1262, 1913], "category": "Picture"}, {"bbox": [101, 1915, 580, 1946], "category": "Text", "text": "Source – Imarc Research, CareEdge Research"}, {"bbox": [89, 1982, 1561, 2114], "category": "Text", "text": "The India In-Vitro Diagnostics (IVD) market, segmented by end-user, is primarily dominated by hospital laboratories, which constitute 39% of the market in CY24, underscoring their critical role in diagnostic services for a wide range of medical conditions. Clinical laboratories follow closely, accounting for 30% of the market, driven by their extensive use in routine and specialized testing. Point-of-care testing centers represent 13% of the market, highlighting the growing demand for decentralized and rapid diagnostic"}]